The first stage of the Phase IIa study with YELIVA ® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous ...
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA ® are expected before year’s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection in 55 clinical sites across the U.S. ...
Key Highlights: Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection on track to be announced in the fourth quarter of 2018 Positive top-line results from Phase III study with RHB-104 for Crohn’s disease - the study successfully met both its primary endpoint ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
Once granted, the new formulation patent is expected to be valid until at least 2033 RHB-106 is an encapsulated bowel preparation with worldwide rights licensed to Salix Pharmaceuticals RedHill and Salix recently amended their license agreement to include certain development activities, timelines ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
Once granted, the new patent, which covers both RHB-104 and RHB-204, is expected to be valid until at least 2029 RedHill recently announced positive top-line results from the randomized, double-blind, placebo-controlled MAP US Phase III study with orally-administered RHB-104 in Crohn’s disease ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...
Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013) Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104 RedHill to host conference call and live webcast today, ...
Menu